Polycythemia vera‐associated pruritus and its management

10.1056/NEJMoa051113

10.1016/S0140-6736(05)71142-9

Vannucchi AM, 2007, Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia, Blood, 3, 840, 10.1182/blood-2006-12-064287

Brumpt L, 1952, [Pruritus in polycythemia.], Presse Med, 66, 1397

10.1046/j.1365-2141.2001.03161.x

Arroyo H, 1971, [The bath sign], Presse Med, 41, 1814

10.1016/S0190-9622(85)70149-1

10.1111/j.1600-0609.1975.tb01054.x

10.1002/ajh.21156

10.1111/j.1365-2133.1987.tb05787.x

10.1002/ajh.2830430419

10.1002/cncr.22365

10.1182/blood.V28.6.795.795

10.1016/S0140-6736(88)92632-3

10.1016/S0140-6736(88)92254-4

Kligman AM, 1986, Water‐induced itching without cutaneous signs. Aquagenic pruritus, Arch Dermatol, 122, 183, 10.1001/archderm.1986.01660140073021

Means R, 2009, Wintrobe’s Clinical Hematology, 2031

10.1159/000247223

10.1016/0140-6736(91)92206-H

10.3109/10428190009148845

10.1136/bmj.282.6281.2008

10.1159/000247891

10.1111/j.1365-4362.1986.tb00863.x

10.1016/S0190-9622(88)70110-3

10.1111/j.1468-3083.2004.01023.x

Diamond JH, 1966, Urticaria pigmentosa complicated by polycythemia vera. Report of a case, Blood, 27, 253, 10.1182/blood.V27.2.253.253

10.1111/j.1600-0560.2007.00927.x

Bircher AJ, 1988, Aquagenic pruritus. Water‐induced activation of acetylcholinesterase, Arch Dermatol, 124, 84, 10.1001/archderm.1988.01670010048020

Ishii T, 2009, Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders, Blood, 23, 5942, 10.1182/blood-2008-09-179416

10.1038/leu.2009.85

10.1002/cncr.21645

10.3324/haematol.2009.007047

10.7326/0003-4819-123-9-199511010-00003

10.1200/JCO.2005.07.062

Wasserman LR, 1981, Influence of therapy on causes of death in polycythemia vera, Trans Assoc Am Physicians, 94, 30

10.1001/archinte.142.2.241

10.1038/leu.2008.280

10.7326/0003-4819-119-11-199312010-00006

10.1002/cncr.22026

10.1007/s002770050563

10.1111/j.1365-2141.1995.tb03306.x

10.1182/blood-2006-03-009860

10.1002/1097-0142(19860215)57:4<718::AID-CNCR2820570406>3.0.CO;2-P

10.1002/ajh.2830410120

10.1002/(SICI)1096-8652(199602)51:2<112::AID-AJH3>3.0.CO;2-0

10.1080/095466301317085408

10.1007/s002770050207

10.1046/j.1365-2133.2002.04983.x

10.1111/j.1365-2133.1993.tb03520.x

10.1182/blood.V99.7.2627

Verstovsek S, 2009, A Phase 2 Study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea, Blood, 114, 631, 10.1182/blood.V114.22.311.311

Pardanani A, 2009, A Phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden ASH, Blood, 114, 755, 10.1182/blood.V114.22.755.755

Vannucchi AM, 2009, RAD001, an inhibitor of mTOR, shows clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (PPV/PET MF), Blood, 114, 10.1182/blood.V114.22.307.307

10.1038/sj.leu.2401045

10.1111/j.1365-2141.1987.00285.x

10.1002/(SICI)1096-8652(199709)56:1<59::AID-AJH12>3.0.CO;2-Y

Verstovsek SKH, 2009, The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post‐polycythemia/essential thrombocythemia myelofibrosis (Post PV/ETMF), Blood, 114

Pardanani AD, 2009, A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden, Blood, 114, 10.1182/blood.V114.22.755.755